$FVRG Ticker: FVRG FVRG Share

New Post Public Reply Private Reply Replies (0) Message Board

Newer Older

StocktraderDK

Jul 10, 2012 at 6:43 AM

$FVRG

Ticker: FVRG

FVRG Share Structure:

Market Value:	$2,070,008	a/o Jul 06, 2012
Shares Outstanding:	14,892,141	a/o May 17, 2012
Authorized Shares	100 Million
Float	6.3 Million	* Insider own 72% of the Outstanding shares *

Short Squeeze Report:

ForeverGreen Worldwide Corp. seems like its been forever shorted, but this time around we feel the time has come where a short squeeze is in due course.

FVRG naked short data shows over 50% of the volume having been naked short sold over the last 4 trading sessions. We believe with the recent increase in corporate activity, coupled with great news, today should show a very positive day for FVRG

Naked Short Data:
http://www.otcshortreport.com/ FVRG

For those of you interested in learning more on FVRG feel free to conduct your own due diligence.
Keep your eye on FVRG today at the bell.

Chart :

Closed right about at its 200 moving day average

Increasing Liquidity and Volume from some awareness

New base forming at .12 range off .08 bottom

RSI 52.61 is tame/neutral will support pps northward movement

PPS has been channeling for about a month from .10 to .16..Looks ready to Spring up

Chart has not had a large volume, could be a huge spike in pps with the small float

Opinion:

We feel this stock is extremely undervalued and lacking awareness in the current price range.
This is a real company with $3.6M dollars in revenue in Q1 of 2012 alone and growing at a rapid pace.
The current Market Value: $2,070,008 a/o Jul 06, 2012 is way out of line for a company that is on pace to do over $20M in Revenue in 2012 as per their Guidance numbers.
The company has all its filings in order and you will even see some insider buying at the .32 price range in Feb. 12.

In conclusion, we are initiating a Strong Buy for FVRG based on market valuation, Q1 2012 Growth Reported in Recent Filings, Anticipated Growth in Revs in Q2 Filings, Chart Technicals, and just the pure lack of awareness of the company.
As we said earlier, ForeverGreen International FVRG , is not interested in pumping their stock with worthless press releases to dilute their shareholder base.. They are a real globally headquarted brick and mortar company growing very fast. FVRG should be one of the few companies that should, in our opinion, be an important part of every serious investor's portfolio.We make the comment because of our prediction that FVRG will grow at an extremely rapid rate during the next 18 months as well as thereafter. We strongly recommend that you seriously consider a holding position for long-term aggressive growth. The company currently trades at fraction of its sales in an industry that typically trades at 2.84 X sales (source: MSN Money). With an average P/E of 20.1 for the S&P and 21.7 for the Food and Packaged Good industry, the stock price could rise considerably. Finally, with $3.6M in revs already filed in Q1 2012 and $20M in guidance for the year, coupled with a 6 Millions Float and a current pps of .139 ....

WE FEEL FVRG IS EXTREMELY UNDERVALUED.... STRONG BUY

Planetpennies have NOT been compensated for FVRG

Disclaimer:

You understand and agree that is possible that at the time of any transaction you may make, PlanetPennies officers, agents, servants, members, affiliates, directors, contractors, employees friends and family members, may have a position in such securities. The positions may have been acquired prior to the publication of any website information or email newsletter. You should also be aware that the aforementioned parties do have the right to increase, decrease, and/or liquidate their positions at any time without further notification.

Read full Disclaimer here :
http://www.planetpennies.com/disclaimer

Forever Green Worldwide (FVRG) Stock Research Links

FVRG Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...